Showing results (31-40 of 68) with videos related to
Sort By:
Pageof 7
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 24, 2018
Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLCJessica J Lin, Viola W Zhu, Adam J Schoenfeld, et al.Journal for Immunotherapy of Cancer|November 1, 2023
Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancerJoao V Alessi, Adam Price, Allison L Richards, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2020
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 FusionsHiroki Sato, Adam J Schoenfeld, Evan Siau, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 10, 2020
Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung CancerMi Ran Yun, Dong Hwi Kim, Seok-Young Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 5, 2025
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum ChemotherapyNatasha B Leighl, Luis Paz-Ares, Delvys Rodriguez Abreu, et al.JAMA Oncology|May 29, 2020
Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers: A Phase 1/2 Single-Group Open-Label TrialHelena A Yu, Adam J Schoenfeld, Alex Makhnin, et al.Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.The Oncologist|August 17, 2023
Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung CancerArielle Elkrief, Biagio Riccuiti, Joao V Alessi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 29, 2022
Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung CancerAdam J Schoenfeld, Hira A Rizvi, Danish Memon, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2019
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic SarcomasNatasha Rekhtman, Joseph Montecalvo, Jason C Chang, et al.Pageof 7